PUBLIC NOTICE

TO ALL DISTRIBUTORS, STOCKISTS, HOSPITALS, AND DEALERS

Subject: Mandatory Revision of Maximum Retail Price (MRP) for Non-Scheduled Anti-Cancer Formulations as per National Pharmaceutical Pricing Authority (NPPA) Directives.

Dear Partners,

In compliance with the **National Pharmaceutical Pricing Authority (NPPA)** order dated October 17, 2026 (Proceeding No: 284/152/2026/F) invoking Trade Margin Rationalisation (TMR) under Paragraph 19 of the DPCO, 2013, **Jodas Expoim Pvt. Ltd.** has revised the Maximum Retail Prices (MRP) for its non-scheduled anti-cancer formulations.The New MRP shall be effective from 9th November,2026. The downstream partners should display these updated price lists in a visible part of their premises so consumers can easily review them.

The trade margins on these products have been capped at 30% of the MRP excluding GST (equivalent to a maximum trade markup of 42.86% on the Price to Stockist / Price to Distributor).

Jodas			Final MRP (Inc GST)
Product	**Strength**	**Pack size**	**PTS/PTD +42.86%+GST=MRP(New)**
Abiraterone acetate	250mg	120's	5,580
Azacitidine	100mg	1's	1,187
Cladribine	10mg	1's	9,660
Dasatinib	20mg	60's	1,152
Fulvestrant	250mg	1's	3,743
pemetrexed	100mg	1's	405
pemetrexed	500mg	1's	1,114
SUNITINIB	12.5mg	7's	396
SUNITINIB	25mg	7's	648
Topotecan	2.5mg	1's	3,420